Myriad to Present New Research at the 2016 ASCO Annual Meeting
May 18 2016 - 5:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced it will present
data from nine clinical studies with three different products at
the 2016 American Society of Clinical Oncology annual meeting to be
held June 3-7, 2016 in Chicago, Ill. Key podium presentations
will highlight the safety and validity of the Myriad
myRisk
® Hereditary Cancer multigene panel test in
assessing hereditary cancer risk. Abstracts of the Company’s
presentations are available at: abstracts.asco.org.
“We’re excited that the studies with myRisk Hereditary Cancer
being presented at ASCO will advance the state-of-the-art of
hereditary cancer testing,” said Johnathan Lancaster, M.D.,
Ph.D., chief medical officer, Myriad Genetic Laboratories. “In
particular, our new data provide additional evidence for expanding
testing to a broader set of patients at risk for developing
hereditary cancers, and for understanding the risks associated with
mutations.”
Myriad’s presentations are listed below. Follow Myriad on
Twitter via @MyriadGenetics to stay informed about news and updates
from the Company.
myRisk Hereditary Cancer
PresentationsPodium Presentations
|
|
Title: |
Yield of multiplex
panel testing exceeds expert opinion and validated prediction
models. |
Presenter: |
Gregory Idos |
Date: |
Sunday, June 5, 2016,
9:45 - 9:57 a.m. |
Location: |
S404,
Abstract:1509 |
|
|
Title: |
Ovarian cancer (OC)
risk associated with mutations detected by multiple-gene germline
sequencing in 95,561 women. |
Presenter: |
Allison Kurian |
Date: |
Monday, June 6, 2016,
10:09 - 10:21 a.m. |
Location: |
E450ab, Abstract:
5510 |
|
|
Title: |
Safety of multiplex
gene testing for inherited cancer risk: interim analysis of a
clinical trial. |
Presenter: |
Allison Kurian |
Date: |
Tuesday, June 7, 2016,
8:36 - 8:48 a.m. |
Location: |
S102,
Abstract:1503 |
|
|
Title: |
Prevalence of germline
mutations in cancer risk genes among unselected colorectal cancer
(CRC) patients (pts). |
Presenter: |
Matthew Yurgelun |
Date: |
Tuesday, June 7, 2016,
8:12 - 8:24 a.m. |
Location: |
S102,
Abstract:1501 |
|
|
Poster Presentations
|
|
Title: |
Genetic heterogeneity
and survival among pancreatic adenocarcinoma (PDAC) patients with
positive family history. |
Presenter: |
Gloria Petersen |
Date: |
Saturday, June 4, 2016,
8:00 - 11:30 a.m. |
Location: |
Hall A, Abstract:4108,
Poster Board 100 |
|
|
Title: |
Detection of somatic
variants in peripheral blood lymphocytes using a next generation
sequencing multigene cancer panel. |
Presenter: |
Bradford Coffee |
Date: |
Monday, June 6, 2016,
8:00 - 11:30 a.m. |
Location: |
Hall A, Abstract:1580,
Poster Board 403 |
|
|
Poster Discussion Presentation
|
|
Title: |
Magnitude of invasive
breast cancer (BC) risk associated with mutations detected by
multiple-gene germline sequencing in 95,561 women. |
Presenter: |
Michael Hall |
Date: |
Monday, June 6, 2016,
8:00 – 11:30 a.m., Discussion 1:15 – 2:30 p.m. |
Location: |
S404, Abstract:1512,
Poster Board 335 |
|
|
myChoice® HRD: Poster Presentation
|
|
Title: |
Clinical significance
of homologous recombination deficiency (HRD) score testing in
endometrial cancer patients. |
Presenter: |
Jean Hansen |
Date: |
Monday, June 6, 2016,
1:00 - 4:00 p.m. |
Location: |
Hall A, Abstract: 5584,
Poster Board 407 |
|
|
Prolaris® Abstract Publication
|
|
Title: |
Reduction in
therapeutic burden from use of CCP test in treatment decisions
among newly diagnosed prostate cancer patients independent of
Charlson Comorbidity Index. |
Presenter: |
Neal Shore |
Abstract: |
e16572 |
|
|
About Myriad myRisk® Hereditary Cancer
TestingThe Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms in an 850 step laboratory process to evaluate 25
clinically significant genes associated with eight hereditary
cancer sites including: breast, colon, ovarian, endometrial,
pancreatic, prostate and gastric cancers and melanoma. For
more information visit:
https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
About
myChoice® HRDMyriad's
myChoice HRD is the first homologous recombination deficiency test
that can detect when a tumor has lost the ability to repair
double-stranded DNA breaks, resulting in increased susceptibility
to DNA-damaging drugs such as platinum drugs or PARP inhibitors.
High myChoice HRD scores reflective of DNA repair deficiencies are
prevalent in all breast cancer subtypes, ovarian and most other
major cancers. In previously published data, Myriad showed
that the myChoice HRD test predicted drug response to platinum
therapy in certain patients with triple-negative breast and ovarian
cancers. It is estimated that 1.8 million people in the
United States and Europe who are diagnosed with cancers annually
may be candidates for treatment with DNA-damaging agents.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra and Prolaris are trademarks or registered
trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G
Safe Harbor StatementThis press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
related to the presentation of data from nine clinical studies at
the 2016 American Society of Clinical Oncology annual meeting to be
held June 3-7, 2016 in Chicago, Ill.; key podium presentations
highlighting the safety and validity of the myRisk Hereditary
multigene panel test in assessing hereditary cancer risk; the
myRisk Hereditary Cancer studies presented at ASCO advancing the
state-of-the-art of hereditary cancer testing; the new data
providing additional evidence for the safety and clinical utility
of the myRisk Hereditary Cancer test to help improve and save the
lives of patients; and the Company's strategic directives under the
caption "About Myriad Genetics." These "forward-looking
statements" are based on management's current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not
limited to: the risk that sales and profit margins of our molecular
diagnostic tests and pharmaceutical and clinical services may
decline; risks related to our ability to transition from our
existing product portfolio to our new tests, including unexpected
costs and delays; risks related to decisions or changes in
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual
Report on Form 10-K for the fiscal year ended June 30, 2015, which
has been filed with the Securities and Exchange Commission, as well
as any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date
of the release, and Myriad undertakes no duty to update this
information unless required by law.
Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024